Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2017, along with a general business update. Aerie Highlights Phase 3 clinical trials required for approval in the U.S. for both RhopressaTM (netarsu